BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25287155)

  • 41. [In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus strains isolated from blood cultures].
    Afşar I; Güngör S; Sener AG; Demirci M
    Mikrobiyol Bul; 2011 Oct; 45(4):755-7. PubMed ID: 22090308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vancomycin MICs of the resistant mutants of S. aureus ATCC43300 vary based on the susceptibility test methods used.
    Zhu YL; Mei Q; Hu LF; Cheng J; Ye Y; Li JB
    J Antibiot (Tokyo); 2012 Jun; 65(6):307-10. PubMed ID: 22491134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.
    Pfaller MA; Rhomberg PR; Huband MD; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid.
    Vanegas Múnera JM; Ocampo Ríos AM; Urrego DM; Jiménez Quiceno JN
    Braz J Infect Dis; 2017; 21(5):493-499. PubMed ID: 28432878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC.
    Chong YP; Park SJ; Kim HS; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):264-6. PubMed ID: 22621914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest® and an automated testing method.
    Bland CM; Porr WH; Davis KA; Mansell KB
    South Med J; 2010 Nov; 103(11):1124-8. PubMed ID: 20890258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
    Camargo IL; Neoh HM; Cui L; Hiramatsu K
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4289-99. PubMed ID: 18824611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced susceptibility to vancomycin in methicillin resistant staphylococcus aureus: a time for action.
    Amatya R; Devkota P; Gautam A
    Nepal Med Coll J; 2014 Sep; 16(1):42-4. PubMed ID: 25799810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Clinical Isolates Among Daptomycin-Naive Patients in Korea.
    Nam EY; Yang SJ; Kim ES; Cho JE; Park KH; Jung SI; Yoon N; Kim DM; Lee CS; Jang HC; Park Y; Lee KS; Kwak YG; Lee JH; Park SY; Hwang JH; Kim M; Song KH; Kim HB
    Microb Drug Resist; 2018 Jun; 24(5):534-541. PubMed ID: 29863982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The change and significance of vancomycin minimal inhibitory concentration against methicillin-resistant Staphylococcus aureus isolates from inpatients with lower respiratory tract infection].
    Yang W; He B; Ning YZ; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Apr; 36(4):288-92. PubMed ID: 23945344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
    Hiramatsu K; Aritaka N; Hanaki H; Kawasaki S; Hosoda Y; Hori S; Fukuchi Y; Kobayashi I
    Lancet; 1997 Dec; 350(9092):1670-3. PubMed ID: 9400512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. hVISA and MRSA endocarditis: an 8-year experience in a tertiary care centre.
    Maor Y; Belausov N; Ben-David D; Smollan G; Keller N; Rahav G
    Clin Microbiol Infect; 2014 Oct; 20(10):O730-6. PubMed ID: 24329974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies.
    Keel RA; Sutherland CA; Aslanzadeh J; Nicolau DP; Kuti JL
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):326-9. PubMed ID: 20955917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
    Vidaillac C; Parra-Ruiz J; Rybak MJ
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
    Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.